GCTKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Glucotrack, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.68−0.04 (-5.56%)

Close on Oct 19, 2026

Market cap: $3.43M
P/E (TTM): 0.0
Dividend yield: –

Glucotrack, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	–	–	–	–	–	–	0.21	0.04	0.59	0.61	0.14	0.06	–	–	–	–	–	–	–	–
Research & Development	9.81	9.50	4.70	1.97	1.81	1.53	1.61	3.03	3.21	2.88	2.27	1.85	1.99	1.92	1.79	0.93	1.01	–	–	–
Selling, General & Admin	–	–	2.40	–	0.14	0.42	2.11	3.55	1.53	1.13	1.13	0.23	1.04	0.85	–	–	–	–	–	–
Selling & Marketing	–	–	0.12	–	0.14	0.42	0.57	1.09	1.53	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	6.28	5.05	2.28	2.47	2.09	1.19	1.54	2.46	6.43	2.26	1.40	1.59	1.04	0.85	0.54	0.46	0.17	–	–	–
Operating Expenses	16	15	7.10	4.43	4.04	3.13	3.71	6.58	11	–	–	–	–	–	–	–	–	–	–	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	11	6.27	4.80	3.67	3.03	2.77	–	–	–	–	–	–
Operating Income	-16	-15	-7.10	-4.43	-4.04	-3.13	3.51	-6.54	11	-5.66	-4.66	-3.61	-3.03	-2.77	-2.33	-1.39	-1.17	–	–	–
Interest Expense	–	0.04	–	–	–	–	–	–	–	–	0.02	0.00	0.02	0.01	0.01	0.02	–	–	–	–
Other Non-Operating Income	-3.30	-8.05	–	-0.01	-0.05	0.34	-0.01	-0.18	0.25	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	–	–	–
Gain (Loss) on Sale of Assets	-0.02	–	–	0.00	-0.04	–	–	–	–	–	–	–	–	–	–	0.00	–	–	–	–
Legal Settlements	–	-4.76	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	–	–	–	–	–	-2.70	-3.52	-6.72	-10	-5.41	-5.84	2.98	-9.80	-2.77	-2.36	-2.79	–	–	–	–
Net Income	-19	-23	-7.10	-4.44	-4.07	-2.70	3.52	-6.72	10	-5.41	-5.84	2.98	-9.80	-2.77	-2.36	-2.79	-1.20	-1.53	-1.59	-1.28
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	0.06	0.37	0.29	–	–	–	–	–	–	–
Net Income to Common	–	-23	-7.95	4.44	–	-2.70	-3.52	-40	-12	-6.23	-6.29	1.97	-10	-2.77	-2.36	–	–	–	–	–
EPS (Basic)(per share)	31.22	4,106.00	2,050.80	87.00	78.00	-0.08	-0.08	-18.47	-7.29	-4.21	-4.48	1.44	-7.60	-2.03	-1.79	-2.73	1.17	–	–	–
EPS (Diluted)(per share)	31.22	4,106.00	2,050.80	87.00	78.00	57.00	-0.08	-18.47	-7.29	-4.21	-4.48	1.44	-7.60	-2.03	-1.79	-2.73	1.17	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	0.62	0.01	0.00	0.05	0.05	50	40	2.16	1.61	1.49	1.41	1.36	1.37	1.36	1.31	1.04	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	0.62	0.01	0.00	0.05	52	50	40	2.16	1.61	1.49	1.41	1.37	1.37	1.36	1.31	1.04	–	–	–	–
EBITDA	–	–	–	–	-4.01	-3.10	–	–	–	–	–	–	–	-2.75	-2.31	-1.34	–	–	–	–
Net Interest Income	–	–	–	–	–	–	0.00	0.02	0.02	-0.02	-0.02	0.00	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 381.2%

Financial strength

Current ratio: 0.46
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 37.6%

Valuation

P/E ratio: 0.0
Price to sales: –
Price to book: –
Dividend yield: –